Previous close | 4.8753 |
Open | 4.8500 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 4.8500 - 4.8500 |
52-week range | 2.7333 - 7.3100 |
Volume | |
Avg. volume | 2,675 |
Market cap | 646,107 |
Beta (5Y monthly) | 0.78 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.9300 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective NANTES, France, April 16, 2024 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, today announced that the Hart-Scott-Rodino waiting period has expired with respect to its global license with AbbVie to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer Nantes, France – April 10, 2024 – 6:00 pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the Company has received €8.4 million in non-dilutive funding under the “i-Démo” call for projects as part of the plan “France 2030” operated by Bpifrance on behalf of the State. This plan aims at developing industrial companies
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1in Journal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the publication of novel data in the peer-reviewed Journal of Immunology (1) on a first-in-class research program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy. The academic collaboration conducted with Dr Elise Chiffo